Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
TRDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.35 - $21.79
Previous CloseN/A
Volume35.15K
Average Volume (3M)113.87K
Market Cap
$489.08M
Enterprise Value$261.23M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)8.2
Beta1.28
Next Earnings
Mar 12, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding37,419,975
10 Day Avg. Volume102,356
30 Day Avg. Volume113,869
Standard Deviation0.24
R-Squared0.00122
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.97
Enterprise Value/Ebitda4.39
Forecast
1Y Price Target
$24.50Price Target Upside87.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Entrada Therapeutics Inc News
PremiumCompany Announcements
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial
PremiumCompany Announcements
Entrada Therapeutics’ Q3 2024 Financial Highlights---
Bulls Say, Bears Say
Bulls Say
Financial StabilityEntrada has a strong cash position of $449 million, providing financial stability and supporting its operations until approximately 2027.
Regulatory ProgressEntrada Therapeutics received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to initiate a Phase 1/2 clinical study of ENTR-601-44.
Bears Say
Regulatory ChallengesAn FDA-issued clinical hold prevents TRDA from initiating clinical trials in the U.S., affecting the company's ability to advance its programs domestically.
---
Ownership Overview
40.54% Insiders
14.31% Mutual Funds
2.75% Other Institutional Investors
34.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $11.35 and its highest was $21.79 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $489.08M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Mar 12, 2025 which is in 18 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Nov 05, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.728 by $0.378.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -0.67.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 37,419,975 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.728. Following the earnings report the stock price went up 4.783%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
---
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.50 (87.45% Upside)
$24.50 (87.45% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 37.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.03%
12-Months-Change
Fundamentals
Return on Equity
16.43%
Trailing 12-Months
Asset Growth
14.34%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
---
TRDA Stock 12 Month Forecast
Average Price Target
$24.50
▲(87.45% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Sarepta Therapeutics
―
Wave Life Sciences
―
Moderna
―
Avidity Biosciences
―
Best Analysts Covering TRDA
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-4.60%
reiterated a buy rating 19 days ago
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.60% per trade.
---